Risperidone Continues to Prove It's Effectiveness for Schizophrenia and Bipolar Disorder for Adults and Children

Risperidone Continues to Prove It's Effectiveness for Schizophrenia and Bipolar Disorder for Adults and Children

Risperidone is sold under the brand name Risperdal in the United States. First developed by Janssen-Cilag, risperidone is an atypical antipsychotic that was initially released in 1994. Risperdal (risperidone) is used for patients suffering from adolescent and adult schizophrenia, schizoaffective disorder, and manic states of bipolar disorder. The FDA approved risperidone in 2003 for short term treatment of the mixed and manic states associated with bipolar disorder. Risperidone joins lithium and divalproex sodium as one of three options for treatment for children ages 10-17 with bipolar disorder. As the first the FDA approved the drug for the treatment of schizophrenia in teenaged children ages 13-17, risperidone offers a low incidence of extrapyramidal side effects when given at low doses. In 2006 the FDA approved the use of risperidone for children with autism who suffer from violent outbursts and severe aggression. Janssen’s patent on four milligram tablets of Risperdal expired at the end of December 2003, thus opening the market up to alternative generic versions of the drug. LGM Pharma supplies Risperidone CAS# 106266-06-2 for R&D purposes, and offers assistance to clients through all stages of research.

Careful dosing of risperidone in patients taking the antidepressants fluoxetine and paroxetine is prudent for providers, as these drugs increase the plasma concentration of risperidone. Caution also needs to be taken when treating elderly patients. Risperidone is not approved for elderly patients suffering from dementia related psychosis. Potential adverse effects from risperidone include muscle pain and tremor, insomnia, high and low blood pressure, weight gain, photosensitivity, rash and alopecia.

A recent study published in the Archives of General Psychiatry on January 2, 2012 indicated risperidone to be more efficacious when compared to lithium or divalproex sodium for the initial treatment of childhood mania. This study, deemed “The Treatment of Early Age Mania”, or TEAM, involved 279 children, ages 6-15. These children were all clinically diagnosed with bipolar 1 disorder, as described in the DSM-IV. Children in this study received a schedule of titrated medications, with risperidone being 4-6 milligram doses. While this study shows risperidone to be the preferred treatment for initial stages of childhood mania, researchers noted potential serious metabolic side effects were possible with the use of risperidone in children. Available as an oral or an injectable, risperidone continues to be an effective drug of choice for both adolescent and adult patients diagnosed with schizophrenia or certain types of bipolar disorder.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service